This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"herapeutic monoclonal antibodies bind proteins on tumors, which can enable the killing of cancer cells. However, there can be collateral damage to healthy tissues that also express those proteins. At CytomX , researchers are exploring the use of a new class of antibodies called Probody™ therapeutics. Masks attached to the ends of a Probody therapeutic can “blindfold” the antibody and reduce its binding to healthy tissues. However, when the antibody encounters a tumor, proteases —enzymes in the tumor microenvironment—can remove these masks to activate the antibody. In this way, Probody therapeutics are designed to maximize anti-cancer activity while minimizing harm to healthy tissue. In a new study, researchers used computer modeling to predict how Probody therapeutics can be tuned to achieve this effect. This model, comprising thousands of equations, estimates the amount of both masked and unmasked (or activated) forms of the antibody in the tumor and in the rest of the body after dosing..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
This resource is a video abstract of a research paper created by …
This resource is a video abstract of a research paper created by Research Square on behalf of its authors. It provides a synopsis that's easy to understand, and can be used to introduce the topics it covers to students, researchers, and the general public. The video's transcript is also provided in full, with a portion provided below for preview:
"Chronic myeloid leukemia (CML) is a rare, spontaneous cancer found in bone marrow. Often the causative mutation generates a fusion protein, BCR-ABL1, with abnormal tyrosine kinase activity, and that abnormal activity is the target of the current tyrosine kinase inhibitor treatments. However, these treatments are expensive if used long term and do not kill cancerous stem cells. Thus, new treatments and treatment targets are needed. One potential category of targets are transcription regulators, such as CDK9 (cyclin-dependent kinase 9). Wogonin is a naturally occurring inhibitor of CDK9, and in a recent study it showed anti-CML effects on cell lines and primary CML cells. Specifically, wogonin induced erythroid differentiation in CML cell lines and primary cells and apoptosis in the KU-812 cell line. Wogonin treatment increased binding between GATA-1 and FOG-1, key players in erythrocyte differentiation and decreased binding between GATA-1 and RUNX1, which regulate megakaryocyte differentiation..."
The rest of the transcript, along with a link to the research itself, is available on the resource itself.
No restrictions on your remixing, redistributing, or making derivative works. Give credit to the author, as required.
Your remixing, redistributing, or making derivatives works comes with some restrictions, including how it is shared.
Your redistributing comes with some restrictions. Do not remix or make derivative works.
Most restrictive license type. Prohibits most uses, sharing, and any changes.
Copyrighted materials, available under Fair Use and the TEACH Act for US-based educators, or other custom arrangements. Go to the resource provider to see their individual restrictions.
